Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor, meets all primary, key ...

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

Viatris' generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been ...

Koby Baranes, PhD, head of science at Clock Bio, cautions, “Aging is not yet fully understood and existing models often fail ...

Department of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, United States ...

Ascletis said it has data indicating denifanstat is 98% more effective at treating acne than sarecycline, and 178% better ...

The article aims to serve as a travelers-health guide to the African continent. Emphasis is on diseases prevalent in the continent, available vaccines and immunization requirements.